Tilray Brands, Inc. Q1FY27 Earnings Call - TILRAY BRANDS INC

Explicit Guidance:

• Reaffirmed fiscal 2027 adjusted EBITDA guidance range of $68 million to $75 million.
• Projected Portugal facility to deliver over 40 metric tons of flower at full capacity in fiscal 2027.
• Anticipated revenue contribution from the Carlsberg partnership to begin immediately upon execution start on January 1, 2027.
• Expects to realize a larger cost and margin impact from new Canadian cultivar transitions late in Q2 2027 and beyond.
• Reported a $52 million principal debt balance outstanding as of quarter-end, with a June 2027 maturity on remaining notes.

Business-Segment Outlook:

• Beverage (BrewDog): Projected to maintain profitability post-acquisition; target for 9,000+ new distribution points and eight new on-trade partnerships already secured in UK; plan to launch over 20 Tilray-owned American craft beers across the UK; intend to expand into India, Poland, France, Israel, and the Middle East via franchise/pub systems.
• International Cannabis: Expecting continued double-digit growth driven by 110% volume increase in flower and 150% in oil (EU GMP shipments) in Portugal/Germany; targeting doubling of Life's patient base in the UK; aiming to capture market share in Germany, Poland, UK, and Italy.
• U.S. Cannabis: Positioning to gain share in Canada through lower-cost cultivation and new strain rollout; anticipating cannabis beverage legalization as a key volume driver if regulations allow access in food establishments, bars, and beer stores in Ontario and other provinces.
• U.S. Beverage: Continuing brewery rationalization (targeting 5–6 facilities down from 8–10); aiming to consolidate distributor relationships; expecting Sweetwater to be the third-largest craft brand in Georgia (12% share) and expanding Montauk, Tweedwater, and Breckenridge in priority markets.
• Wellness: Planning expansion of Manitoba Harvest into adjacent grains, plant-based products, and new wellness occasions; targeting growth in grocery, natural, and e-commerce channels.
• Distribution (CC Pharma): Leveraging access to 16,000 pharmacies to support medical cannabis and broader pharmaceutical growth; aiming to strengthen margins through favorable product mix and cost reduction initiatives.

Market and Competitive Outlook:

• Pricing/Supply: Anticipating international cannabis price compression of $8.8 million in Q1 with expectations for continued pressure in some markets; offsetting via operating efficiencies and mix improvement.
• Competitive Dynamics: Expecting U.S. craft beer category reshuffling via distributor consolidation; Tilray positioned as #2 craft vendor in Georgia/West and #4 in New York based on recent data.
• Structural Shifts: Belief that the U.S. cannabis market will eventually allow beverage formats, creating a hundreds of millions to $1 billion opportunity; view that Canada will expand beyond traditional formats into cannabis beverages in regulated outlets to replace alcohol excise tax revenue.
• Synergies: Expecting top-line synergies between beverage and cannabis globally through shared infrastructure and cross-promotion in markets where both are legal.

Macro / Industry Outlook:

• Regulatory (U.S.): Monitoring hemp bill extension (expected beyond December 11, 2026) and potential THC beverage carve-outs; confident in a $1 billion+ opportunity if legislation passes allowing hemp-derived THC beverages.
• Regulatory (Global): Expecting sustained growth in regulated medical markets (Europe, Canada) with high standards favoring low-cost, high-quality producers; noting Germany reimbursement changes (effective July 1, 2026) will have limited impact as majority of patients are cash pay.
• Economic/External Headwinds: Citing fuel surcharges increasing by $1.7 million year-over-year as a discrete cost headwind; monitoring geopolitical impacts on input costs.
• Rates/FX: Operating across 25 countries with multiple currencies; managing utility and fuel cost fluctuations.

Strategic Initiatives:

• Carlsberg Partnership: Exclusive multi-year agreement starting Jan 1, 2027, for Tilray to produce, market, and sell Carlsberg, Carlsberg Elephant, and 1664 Blanc across all U.S. channels; expected to provide immediate scale and deepen retailer relationships.
• Acquisitions/M&A: Focusing on "focused M&A" using operating capabilities to integrate assets; no immediate large-capex M&A announced, but maintaining open evaluation of opportunities in India, Israel, and Poland via partnerships.
• Capacity Additions: Portugal facility optimization to reduce operating costs by ~40%; Quebec facility (Maison) targeting EU GMP certification within the year; Germany's Apria RX operating at 100% capacity.
• Cost Control: Streamlining operating structure, optimizing production, and rationalizing brand portfolios; targeting $50 billion (sic, likely typo in transcript for $50 million) of short-term funding reduction post-BrewDog integration.
• Innovation: Launching ready-to-drink, non-alcoholic, and seltzer categories; leveraging R&D to create proprietary products (e.g., vodka seltzer) rather than acquiring.

Risks and Headwinds to Outlook:

• Regulatory Delays: Potential delays in U.S. cannabis rescheduling or hemp bill extensions could impact sentiment and timing of U.S. beverage/cannabis beverage opportunities.
• Price Compression: Continued price compression in international cannabis markets could offset volume gains.
• Input Costs: Volatility in fuel surcharges and input costs (hops, cans) may impact beverage gross margins.
• Market Competition: Consolidation in U.S. beer distribution and competitive intensity in Canadian adult-use market.
• Integration Risk: Ongoing execution risk in integrating BrewDog operations and realizing synergies between beverage and cannabis portfolios.

Management Tone on the Future:

• Confidence Level: High confidence in delivering the $68–$75 million adjusted EBITDA range despite external headwinds; described underlying business direction as "strong."
• Strategic Conviction: Reiterated that Tilray is a diversified global business, not a pure-play U.S. cannabis operator; management expresses readiness to "pounce" on any U.S. regulatory changes while simultaneously growing international and beverage segments.
• Operational Discipline: Emphasis on converting platform scale into margin expansion and cash flow; notes "clear proof points" in U.S. beer turnaround and BrewDog profitability.
• Hedges: Management explicitly states strategy is "not dependent upon one regulatory event" and will continue to grow regardless of specific U.S. outcomes.

Miscellaneous:

• Balance Sheet Strength: Ended Q1 with $221 million in cash/restricted cash; settled >$42 million debt year-to-date; actively evaluating capital structure improvements.
• Global Reach: Operating in 25 countries; nearly 40 hospitality venues (pubs, bars, hotels) serving as brand touchpoints.
• Cost Leadership: Portugal facility established as one of the lowest-cost cannabis producers in Europe; aiming to leverage this for global export.
• Tax Contribution: Tilray pays over $100 million CAD in excise tax in Canada, highlighting the legal industry's role in government revenue.